Medical Policy

Transcutaneous Electrical Nerve Stimulation

Table of Contents

- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References

Policy Number: 003

BCBSA Reference Number: 1.01.09

NCD/LCD:
- National Coverage Determination (NCD) for Assessing Patient's Suitability for Electrical Nerve Stimulation Therapy (160.7.1)
- National Coverage Determination for Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative Pain (10.2)
- National Coverage Determination for Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES) (160.13)

Related Policies

- Interferential Stimulation for Treatment of Pain, #509
- Temporomandibular Joint Dysfunction, #035
- Percutaneous Electrical Nerve Stimulation or Percutaneous Neuromodulation Therapy, #172

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

A trial of transcutaneous electrical nerve stimulation (TENS) of at least 30 days may be considered MEDICALLY NECESSARY to establish efficacy for the management of refractory chronic pain (e.g., chronic musculoskeletal or neuropathic pain) that causes significant disruption of function when the following conditions have been met:
- The pain is unresponsive to at least 3 months of conservative medical therapy, AND
- The trial is monitored by a physician.

Refractory chronic pain is defined in this policy as pain that causes significant disruption of function and has not responded to at least 3 months of conservative therapy, including nonsteroidal anti-inflammatory medications, ice, rest, and/or physical therapy.

Documentation for the trial should include:
- Initial assessment/evaluation of the nature, duration, and perceived intensity of pain;
- The types and duration of prior treatments;
- Treatment plan including ongoing medications and proposed use of TENS unit, including the frequency and duration of treatment.
Clinical summary of the trial to determine efficacy should include:

- Perceived intensity of pain with and without TENS (e.g., 2 point or 30% improvement in visual analog scale [VAS]),
- Ongoing medication requirements for pain relief (if any),
- Other modalities (if any) in use for pain control, and
- Actual use of TENS on a daily basis (frequency and duration of application).

Continued use of TENS may be considered **MEDICALLY NECESSARY** for treatment of refractory chronic pain (e.g., chronic musculoskeletal or neuropathic pain) that causes significant disruption of function when the following conditions have been met:

- Efficacy has been demonstrated in an initial therapeutic trial; AND
- Compliance has been demonstrated in the therapeutic trial with the device used on a regular basis (eg, daily or near daily use) throughout the trial period.

**Note:** A TENS billed as a purchased unit (modifier NU) must meet above criteria for continued use.

TENS is **INVESTIGATIONAL** for the management of acute pain (e.g., postoperative or during labor and delivery).

The use of TENS for any other condition, including but not limited to the treatment of dementia and prevention of migraine headaches, is **INVESTIGATIONAL**.

**Medicare HMO BlueSM and Medicare PPO BlueSM Members**

Medical necessity criteria and coding guidance can be found through the link below.

**National Coverage Determinations (NCDs)**

- National Coverage Determination (NCD) for Assessing Patient’s Suitability for Electrical Nerve Stimulation Therapy (160.7.1)
- National Coverage Determination for Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative Pain (10.2)
- National Coverage Determination for Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES) (160.13)

**Note:** To review the specific NCD, please remember to click “accept” on the CMS licensing agreement at the bottom of the CMS webpage.

**Prior Authorization Information**

**Inpatient**
- For services described in this policy, precertification/preauthorization is **REQUIRED** for all products if the procedure is performed **inpatient**.

**Outpatient**
- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

| **Commercial Managed Care (HMO and POS)**       | Prior authorization is **not required**. |
| **Commercial PPO and Indemnity**                | Prior authorization is **not required**. |
| **Medicare HMO BlueSM**                         | Prior authorization is **not required**. |
| **Medicare PPO BlueSM**                         | Prior authorization is **not required**. |
CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

**HCPCS Codes**

<table>
<thead>
<tr>
<th>HCPCS codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A4595</td>
<td>Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES)</td>
</tr>
<tr>
<td>A4630</td>
<td>Replacement batteries, medically necessary, transcutaneous electrical stimulator, owned by patient</td>
</tr>
<tr>
<td>E0720</td>
<td>Transcutaneous electrical nerve stimulator (TENS) device, two lead, localized stimulation</td>
</tr>
<tr>
<td>E0730</td>
<td>Transcutaneous electrical nerve stimulation (TENS) device, four or more leads, for multiple nerve stimulation</td>
</tr>
<tr>
<td>E0731</td>
<td>Form-fitting conductive garment for delivery of TENS or NMES (with conductive fibers separated from the patient's skin by layers of fabric)</td>
</tr>
</tbody>
</table>

The following CPT code is considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

**CPT Codes**

<table>
<thead>
<tr>
<th>CPT codes:</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0278T</td>
<td>Transcutaneous electrical modulation pain reprocessing (eg, scrambler therapy), each treatment session (includes placement of electrodes)</td>
</tr>
</tbody>
</table>

**Description**

Transcutaneous electrical nerve stimulation (TENS) has been used to treat chronic intractable pain, postsurgical pain, and pain associated with active or posttrauma injury unresponsive to other standard pain therapies. It has been proposed that TENS may provide pain relief through the release of endorphins in addition to potential blockade of local pain pathways. TENS has also been used to treat dementia by altering neurotransmitter activity and increasing brain activity that is thought to reduce neural degeneration and stimulate regenerative processes.

Percutaneous electrical nerve stimulation (see policy #172) is similar to TENS but uses microneedles that penetrate the skin instead of surface electrodes. Interferential stimulation (see policy #509) uses a modulated waveform for deeper tissue stimulation, and the stimulation is believed to improve blood flow to the affected area.

**Summary**

Transcutaneous electrical nerve stimulation (TENS) describes the application of electrical stimulation to the surface of the skin at the site of pain. In addition to more traditional settings such as a physician’s office or an outpatient clinic, TENS can be self-administered in a patient’s home.

For individuals who have chronic pain (eg, musculoskeletal, neuropathic, and mixed pain conditions) who receive TENS, the evidence includes numerous randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and medication use. The overall strength of the evidence is weak. The best evidence exists for treatment of chronic, intractable pain. Available evidence indicates that TENS can improve chronic intractable pain in some patients, and
there is support for its use in clinical guidelines by specialty societies. To best direct TENS toward patients who will benefit, a short-term trial of TENS is appropriate, with continuation only in patients who show an initial improvement. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Clinical input obtained in 2009 and 2011 was, for the most part, in agreement that TENS is a generally accepted treatment modality and can be beneficial for the management of chronic pain in some patients. A trial period, similar to that listed in Medicare Coverage guidelines, was recommended by some.

For individuals who have acute pain (eg, surgical, musculoskeletal, labor, and mixed pain conditions) who receive TENS, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms and medication use. Overall, evidence for the use of TENS from high-quality trials remains inconclusive for most indications. A Cochrane review of TENS for acute pain (eg, cervical laser treatment, venipuncture, screening flexible sigmoidoscopy, postpartum uterine contractions, rib fractures) found some evidence that TENS reduces pain intensity over and above that seen with placebo, but the high risk of bias made definitive conclusions impossible. For the treatment of pain after total knee arthroplasty, 2 large RCTs found no benefit of TENS compared with sham TENS. A subsequent systematic review found that TENS reduced pain in the immediate postoperative period (24 hours) after total knee arthroplasty compared with control intervention, however, neither the intensity nor optimal duration time for TENS have been established. For the prevention of migraine headaches, a small RCT reported a greater proportion of patients achieving at least a 50% reduction in migraines with TENS than with sham placebo, and modest reductions in the number of total headache and migraine days. This manufacturer-sponsored trial needs corroboration before conclusions can be made about the efficacy of TENS for preventing migraine headaches. For the relief of pain during office-based hysteroscopy, an RCT found decreased pain and higher patient satisfaction in patients receiving TENS compared with placebo or control. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input obtained in 2009 was generally in agreement that TENS is investigational for the management of acute pain and for other conditions such as dementia.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/2018</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>1/2018</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>8/2016</td>
<td>Clarified coding information.</td>
</tr>
<tr>
<td>12/2015</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>12/2015</td>
<td>Added coding language.</td>
</tr>
<tr>
<td>6/2015</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
<tr>
<td>5/2014</td>
<td>Updated Coding section with ICD10 procedure and diagnosis codes. Effective 10/2015.</td>
</tr>
<tr>
<td>12/2013</td>
<td>Medically necessary indications clarified.</td>
</tr>
<tr>
<td>10/2013</td>
<td>New references from BCBSA National medical policy.</td>
</tr>
</tbody>
</table>
Information Pertaining to All Blue Cross Blue Shield Medical Policies
Click on any of the following terms to access the relevant information:

Medical Policy Terms of Use
Managed Care Guidelines
Indemnity/PPO Guidelines
Clinical Exception Process
Medical Technology Assessment Guidelines

References


64. Chesterton LS, Lewis AM, Sim J, et al. Transcutaneous electrical nerve stimulation as adjunct to primary care management for tennis elbow: pragmatic randomised controlled trial (TATE trial). BMJ. Sep 02 2013;347:f5160. PMID 23999980
